EUVIMEDEUVIMED entdecken
Crossref

Cell Membrane‐Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis‐Enhanced Photodynamic Immunotherapy

Jian Chen iD, Zeyu Duan, Lidong Deng, Lie Li, Qiyan Li, Jinqing Qu iD, Xiang Li, Ruiyuan Liu iD

Advanced Healthcare Materials · 2024-06 · 13 (16)

DOI: 10.1002/adhm.202304436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.05.2024. Verfasst von Jian Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Photochemotherapy, S100 Calcium-Binding Protein A4, Photosensitizing Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Hainan Medical University, President Fund of Nanfang Hospital, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An imbalance in reactive oxygen species (ROS) levels in tumor cells can result in the accumulation of lipid peroxide (LPO) which can induce ferroptosis. Moreover, elevated ROS levels in tumors present a chance to develop ROS‐based cancer therapeutics including photodynamic therapy (PDT) and ferroptosis. However, their anticancer efficacies are compromised by insufficient oxygen levels and inherent cellular ROS regulatory mechanism. Herein, a cell membrane‐targeting photosensitizer, TBzT‐CNQi, which can generate 1 O 2 , •OH, and O 2 •− via type I/II process to induce a high level of LPO for potent ferroptosis and photodynamic therapy is developed. The FSP1 inhibitor (iFSP1) is incorporated with TBzT‐CNQi to downregulate FSP1 expression, lower the intracellular CoQ10 content, induce a high level of LPO, and activate initial tumor immunogenic ferroptosis. In vitro and in vivo experiments demonstrate that the cell membrane‐targeting type I/II PDT combination with FSP1 inhibition can evoke strong ICD and activate the immune response, which subsequently promotes the invasion of CD8+ T cells infiltration, facilitates the dendritic cell maturation, and decreases the tumor infiltration of tumor‐associated macrophages. The study indicates that the combination of cell membrane‐targeting type I/II PDT and FSP1 inhibition holds promise as a potential strategy for ferroptosis‐enhanced photodynamic immunotherapy of hypoxia tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisPhotochemotherapyS100 Calcium-Binding Protein A4Photosensitizing AgentsAnimalsMiceHumansCell Line, TumorCell MembraneImmunotherapyReactive Oxygen SpeciesFemale

Stichwörter der Autor:innen

FSP inhibitioncell membrane‐targetingferroptosisphotodynamic therapytype I/II photosensitizers

Substanzen

S100 Calcium-Binding Protein A4Photosensitizing AgentsReactive Oxygen SpeciesS100A4 protein, human

Autor:innen und Institutionen

  • Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, P. R. China.
  • School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, 510640, P. R. China.
  • Department of Emergency Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
  • Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University, Haikou, 571199, China.

ORCID-Profile: Jian Chen, Jinqing Qu, Ruiyuan Liu

Förderung

  • Hainan Medical University
  • President Fund of Nanfang Hospital
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Chen, J., Duan, Z., Deng, L., Li, L., Li, Q., Qu, J., Li, X., & Liu, R. (2024). Cell Membrane‐Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis‐Enhanced Photodynamic Immunotherapy. Advanced Healthcare Materials, 13(16). https://doi.org/10.1002/adhm.202304436

Vancouver

Chen J, Duan Z, Deng L, Li L, Li Q, Qu J, et al. Cell Membrane‐Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis‐Enhanced Photodynamic Immunotherapy. Advanced Healthcare Materials. 2024;13(16). doi:10.1002/adhm.202304436

BibTeX
@article{Chen2024,
  author = {Chen, Jian and Duan, Zeyu and Deng, Lidong and Li, Lie and Li, Qiyan and Qu, Jinqing and Li, Xiang and Liu, Ruiyuan},
  title = {Cell Membrane‐Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis‐Enhanced Photodynamic Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {16},
  doi = {10.1002/adhm.202304436}
}
Kostenlos starten →